• Skip to primary navigation
  • Skip to main content

National Forum

  • Home
  • About
    • Advisory Leadership Council
    • Board of Directors
    • 2021-22 Strategic Plan
    • History
    • National Forum Awards
    • Team
    • Support
    • Careers
  • Collaborations
    • Awareness Months 2023
    • Counter Cholesterol™
    • Flu Prevention
    • Know Your Numbers
    • Million Hearts®
      • Million Hearts® Stakeholders Flu Vaccination Campaign ’22
    • Move with the Mayor™
    • Signature Reports
    • Stronger Hearts™
    • Value & Access
    • Value & Innovation Forum
  • Events
    • National Forum and Member Events
    • Health Equity Benefits Everyone – January 2023
    • 2022 Annual Meeting
    • 2022 Mid-Year Virtual Convening
    • 2021 Annual Meeting
    • 2021 Mid-Year Virtual Convening
    • Heart Failure Roundtable
    • Value & Innovation Forum
    • Meeting Archives
      • 2020 Annual Meeting
      • 2020 Mid-Year Meeting
      • 2019 Annual Meeting
      • 2019 Virtual Convening on Stroke
      • 2019 Mid-Year Member Meeting
      • 2018 Annual Meeting
      • 2018 Mid Year Meeting
  • Members
    • Membership
  • Newsroom
  • Search Toggle
  • Skip to content

National Forum Statement on Amgen’s Repatha Price Change

Posted on 10.26.18

The National Forum issued the following statement in response to Amgen’s announcement that it cut the price of its cholesterol-lowering drug, Repatha, by 60 percent.

Leaders representing patients, providers, public health, payers and pharma/biotech have joined forces through the National Forum Value & Access Initiative to enhance health and well-being by supporting people’s access to evidence-based care that is appropriate for them.

The price change announced by Amgen appears to support the Value & Access Initiative’s consensus strategy, to align incentives for all stakeholders

  • It appears designed to reduce consumers’ out-of-pocket costs.
  • It may mean that health plans and pharmacy benefit managers can better provide evidence-based drug therapy for patients who may benefit most.
  • Amgen’s assumption that increased sales will offset reduced margins may mean this new pricing strategy will preserve incentives for future innovation

The National Forum and its members will watch eagerly, hoping to see improved access to this cholesterol-lowering therapy for the people who may benefit most.

Categories: In the News, Value & Access

1150 Connecticut Ave., NW, Suite 300, Washington, DC 20036 Phone: (866) 894-3500
Copyright © 2023 National Forum for Heart Disease & Stroke Prevention. All Rights Reserved
  • Facebook
  • Twitter
  • YouTube
Contact

"*" indicates required fields

Name * Required
This field is for validation purposes and should be left unchanged.